Whistler Conference Centre Floorplan
This meeting took place in 2009
Here are the related meetings in 2023:
Next Generation Antibody Therapeutics: From Discovery to Patient (Q5)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Antibodies as Drugs (X7)
Organizer(s) James D. Marks, E. Sally Ward and Louis M. Weiner
March 27—April 1, 2009
Whistler Conference Centre • Whistler, BC Canada
Abstract Deadline: Dec 1, 2008
Late Abstract Deadline: Dec 29, 2008
Scholarship Deadline: Dec 1, 2008
Early Registration Deadline: Jan 27, 2009
Sponsored by Pfizer Global Research & Development
Joint Meeting:
Targeted Cancer Therapies (X8)
Summary of Meeting:
Despite being theorized more than 100 years ago as the “magic bullets” to treat a range of diseases, it is only within the last 10 years that antibodies have become an important class of therapeutics. This meeting will bring together experts from academia and industry to discuss the current state of antibody therapeutics, their mechanism of action in a range of medical indications, novel approaches to improving discovery, manufacturing, formulation, and pharmacokinetics, methods to predict and increase therapeutic efficacy, as well as novel therapeutic opportunities in cancer, infectious diseases, allergy, inflammatory diseases, and the neurosciences. This meeting will be of interest to academic and industry scientists working in all these fields.
View Scholarships/Awards
Despite being theorized more than 100 years ago as the “magic bullets” to treat a range of diseases, it is only within the last 10 years that antibodies have become an important class of therapeutics. This meeting will bring together experts from academia and industry to discuss the current state of antibody therapeutics, their mechanism of action in a range of medical indications, novel approaches to improving discovery, manufacturing, formulation, and pharmacokinetics, methods to predict and increase therapeutic efficacy, as well as novel therapeutic opportunities in cancer, infectious diseases, allergy, inflammatory diseases, and the neurosciences. This meeting will be of interest to academic and industry scientists working in all these fields.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
FRIDAY, MARCH 27
SATURDAY, MARCH 28
SUNDAY, MARCH 29
MONDAY, MARCH 30
TUESDAY, MARCH 31
WEDNESDAY, APRIL 1
Conference Program Print | View meeting in 12 hr (am/pm) time
FRIDAY, MARCH 27
19:30—20:30
Keynote Address (Joint)
*
James D. Marks,
University of California, San Francisco, USA
Session Chair
Session Chair
*
Barbara L. Weber,
Tango Therapeutics, USA
Session Chair
Session Chair
David P. Lane,
Agency for Science, Technology and Research, Singapore
Target Validation in Cancer Treatment: The Use of Chemical Biology and Protein Aptamer Approaches
Target Validation in Cancer Treatment: The Use of Chemical Biology and Protein Aptamer Approaches
08:00—11:15
Novel Cancer Drug Scaffolds (Joint)
*
James D. Marks,
University of California, San Francisco, USA
Session Chair
Session Chair
Nick Terrett,
Ensemble Discovery Corporation, USA
A DNA-Programmed Chemistry Approach to Macrocyclic Lead Compounds
A DNA-Programmed Chemistry Approach to Macrocyclic Lead Compounds
Rodney W. Lappe,
CovX Research LLC, Pfizer, USA
Using CovX-Body Technology to Target the Angiopoietin Axis
Using CovX-Body Technology to Target the Angiopoietin Axis
Yollete V. Guillen Schlippe,
Massachusetts General Hospital, USA
Short Talk: Selection of Cyclic Peptides Composed of Multiple Unnatural Amino Acids that Display Antibody-Like Affinity
Short Talk: Selection of Cyclic Peptides Composed of Multiple Unnatural Amino Acids that Display Antibody-Like Affinity
Jennifer R. Cochran,
Stanford University, USA
Short Talk: Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects
Short Talk: Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects
14:30—16:30
Workshop 1: Novel Approaches to Cancer Drug Development (Joint)
*
Louis M. Weiner,
Georgetown University Medical Center, USA
Session Chair
Session Chair
Steve K. Horrigan,
Avalon Pharmaceuticals, USA
Systems Biology for Lead Optimization
Systems Biology for Lead Optimization
Lutz Jermutus,
MedImmune LLC, UK
Discovering Cancer Therapeutics by Phage and Ribosome Display as well as Transgenics Technologies
Discovering Cancer Therapeutics by Phage and Ribosome Display as well as Transgenics Technologies
Ravi Majeti,
Stanford University, USA
Blocking Monoclonal Antibodies Directed Against CD47 Preferentially Enable Phagocytosis and Elimination of Human Acute Myeloid Leukemia Stem Cells
Blocking Monoclonal Antibodies Directed Against CD47 Preferentially Enable Phagocytosis and Elimination of Human Acute Myeloid Leukemia Stem Cells
Teemu T. Junttila,
Genentech, Inc., USA
Superior in vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2 Amplified Breast Cancer
Superior in vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2 Amplified Breast Cancer
Mariia Yuneva,
Francis Crick Institute, UK
Combining Metabolomics with Microarray Analysis to Determine Metabolic Cancer Targets in vivo
Combining Metabolomics with Microarray Analysis to Determine Metabolic Cancer Targets in vivo
17:00—19:00
Generating and Engineering Novel Antibody Binding Sites
*
Lutz Jermutus,
MedImmune LLC, UK
Session Chair
Session Chair
George Georgiou,
University of Texas at Austin, USA
Selection, Fc Engineering and Preparative Expression of Full Length IgG in E.coli
Selection, Fc Engineering and Preparative Expression of Full Length IgG in E.coli
James D. Marks,
University of California, San Francisco, USA
Selecting Internalizing Antibodies for Drug Delivery
Selecting Internalizing Antibodies for Drug Delivery
Max Woisetschlager,
F-Star, Austria
Antigen Binding by Modified Immunoglobulin Fc (Fcab) and Complete IgGs with Additional Binding Sites
Antigen Binding by Modified Immunoglobulin Fc (Fcab) and Complete IgGs with Additional Binding Sites
Roger R. Beerli,
NBE-Therapeutics AG, Switzerland
Short Talk: Isolation and Preclinical Validation of Therapeutic Human Monoclonal Antibodies Isolated by Mammalian Cell Display
Short Talk: Isolation and Preclinical Validation of Therapeutic Human Monoclonal Antibodies Isolated by Mammalian Cell Display
17:00—19:15
The Chemistry of Targeted Drug Discovery
Saul H. Rosenberg,
Abbott Laboratories, USA
Targeting Apoptosis: Bcl-2 Family Protein Inhibitors
Targeting Apoptosis: Bcl-2 Family Protein Inhibitors
Nathanael Gray,
Stanford University, USA
Tackling the Kinome: Bcr-Abl, EML4-ALK in EGFR
Tackling the Kinome: Bcr-Abl, EML4-ALK in EGFR
Kathlynn C. Brown,
University of Texas Southwestern Medical Center, USA
Short Talk: Isolation of a Suite of Cell Binding Peptides: Novel Ligands for Diagnosis and Targeted Therapy for Non-Small Cell Lung Cancer
Short Talk: Isolation of a Suite of Cell Binding Peptides: Novel Ligands for Diagnosis and Targeted Therapy for Non-Small Cell Lung Cancer
Suzanne Forry-Schaudies,
National Cancer Institute, National Institutes of Health, USA
Short Talk: NCI Chemical Biology Consortium (CBC)
Short Talk: NCI Chemical Biology Consortium (CBC)
08:00—11:15
Engineering Fc Regions for Optimized ADCC and PK
*
Raphael Clynes,
Xencor, Inc., USA
Session Chair
Session Chair
Louis M. Weiner,
Georgetown University Medical Center, USA
Optimizing in vitro and in vivo ADCC for Cancer Therapy
Optimizing in vitro and in vivo ADCC for Cancer Therapy
John R. Desjarlais,
Xencor, Inc., USA
Engineered Fc Domains for Enhanced Cytotoxicity and Pharmacokinetics
Engineered Fc Domains for Enhanced Cytotoxicity and Pharmacokinetics
Pablo Umaña,
Roche Innovation Center Zürich, Switzerland
New Glycoengineered Antibodies with Enhanced Effector Functions
New Glycoengineered Antibodies with Enhanced Effector Functions
E. Sally Ward,
University of Southampton, UK
The Role of FcRn in IgG Homeostasis: Implications for the Use of Antibodies in Therapy
The Role of FcRn in IgG Homeostasis: Implications for the Use of Antibodies in Therapy
Jeanette H.W. Leusen,
University Medical Center Utrecht, Netherlands
Short Talk: The Fc Receptor gamma-Chain ITAM is Required for Antibody Immunotherapy
Short Talk: The Fc Receptor gamma-Chain ITAM is Required for Antibody Immunotherapy
Shu-ichi Hashimoto,
Chiome Bioscience Inc., Japan
Short Talk: ADLib System: New Antibody Generating Technology based on Cell Surface Displayed Antibody Library
Short Talk: ADLib System: New Antibody Generating Technology based on Cell Surface Displayed Antibody Library
08:00—11:15
Cancer Targets
*
Gordon B. Mills,
University of Texas MD Anderson Cancer Center, USA
Session Chair
Session Chair
Craig B. Thompson,
Memorial Sloan Kettering Cancer Center, USA
Mitochondrial Targets
Mitochondrial Targets
Pierre Sonveaux,
University of Louvain, Belgium
Lactate-Fueled Tumor Cell Respiration: A New Paradigm and a New Target for Therapy
Lactate-Fueled Tumor Cell Respiration: A New Paradigm and a New Target for Therapy
Neal Rosen,
Memorial Sloan-Kettering Cancer Center, USA
Role of Feedback and Redundancy in Oncoprotein Activated Signaling Pathways
Role of Feedback and Redundancy in Oncoprotein Activated Signaling Pathways
D. Gary Gilliland,
Merck & Co., Inc., USA
Genome Wide shRNA-Based Synthetic Lethality Screens to Target "Undruggable" Cancer Disease Alleles
Genome Wide shRNA-Based Synthetic Lethality Screens to Target "Undruggable" Cancer Disease Alleles
Daniel Monticello,
Molecular Logix Inc, USA
Short Talk: Development of a Pan-HER Dominant Negative Ligand that Inhibits HER Phosphorylation and HER-Ligand Dependent Tumor Cell Growth
Short Talk: Development of a Pan-HER Dominant Negative Ligand that Inhibits HER Phosphorylation and HER-Ligand Dependent Tumor Cell Growth
Peter R. Rhode,
Altor BioScience Corp., USA
Short Talk: IL-15 Superagonist as a Targeted Immunotherapeutic Molecule
Short Talk: IL-15 Superagonist as a Targeted Immunotherapeutic Molecule
14:30—16:30
Workshop 2: Bispecific Antibodies and Antibody Combinations: The How and the Why
*
James D. Marks,
University of California, San Francisco, USA
Session Chair
Session Chair
Robert Mabry,
ZymoGenetics, Inc., USA
Selection of Stable Antibody Fragments for Assembly of Dual-Targeting Therapeutics
Selection of Stable Antibody Fragments for Assembly of Dual-Targeting Therapeutics
Carston R. Wagner,
University of Minnesota, USA
Chemically Controlled Assembly of Single-Chain Antibody Nanorings
Chemically Controlled Assembly of Single-Chain Antibody Nanorings
Wei Yan,
Amgen Inc., USA
Design and Engineering of Fc Heterodimers for the Production of Bispecific Antibodies
Design and Engineering of Fc Heterodimers for the Production of Bispecific Antibodies
Aran Frank Labrijn,
Genmab, Netherlands
Therapeutic IgG4 Antibodies Engage in Fab-Arm Exchange with Patient's IgG4 in vivo
Therapeutic IgG4 Antibodies Engage in Fab-Arm Exchange with Patient's IgG4 in vivo
Ann P. MacLaren,
Biogen Idec, USA
A Novel Tetravalent Anti-CD23 Antibody Induces Potent Anti-Tumor Activity in CD23+ Tumor Cells via Hyper Cross-Linking of CD23
A Novel Tetravalent Anti-CD23 Antibody Induces Potent Anti-Tumor Activity in CD23+ Tumor Cells via Hyper Cross-Linking of CD23
Klaus Koefoed,
Symphogen A/S, Denmark
Development of Sym004 - a Dual Antibody Combination Targeting the Epidermal Growth Factor Receptor with Strong Anti-Tumor Efficacy in a Xenograft Mouse Model
Development of Sym004 - a Dual Antibody Combination Targeting the Epidermal Growth Factor Receptor with Strong Anti-Tumor Efficacy in a Xenograft Mouse Model
Rob Roovers,
Merus BV, Netherlands
Combining Different Modes of EGFR Inhibition into a Single Nanobody-Based Molecule Yields a Promising Anti-Cancer Drug
Combining Different Modes of EGFR Inhibition into a Single Nanobody-Based Molecule Yields a Promising Anti-Cancer Drug
17:00—19:00
Immune System Activation to Elicit Therapeutic Responses
*
E. Sally Ward,
University of Southampton, UK
Session Chair
Session Chair
Raphael Clynes,
Xencor, Inc., USA
Conversion of Passive Antibody Therapy to Active Immunity
Conversion of Passive Antibody Therapy to Active Immunity
Gerard Zurawski,
Baylor Institute for Immunology Research, USA
Vaccines Based on Targeting Antigens Directly to DCs
Vaccines Based on Targeting Antigens Directly to DCs
Kavita Dhodapkar,
Emory University, USA
Antibody-Based Induction of Adaptive Immune Response
Antibody-Based Induction of Adaptive Immune Response
Mark S. Cragg,
University of Southampton, UK
Short Talk: The Role of Activatory and Inhibitory FcgR in Antibody Immunotherapy
Short Talk: The Role of Activatory and Inhibitory FcgR in Antibody Immunotherapy
17:00—19:00
Autophagy and Metabolism
Matthew G. Vander Heiden,
Massachusetts Institute of Technology, USA
Targeting Cancer Cell Metabolism
Targeting Cancer Cell Metabolism
Gordon B. Mills,
University of Texas MD Anderson Cancer Center, USA
Targeting Energy Sensing
Targeting Energy Sensing
Chi Van Dang,
Ludwig Institute for Cancer Research, USA
Therapeutic Implications of the Warburg Effect
Therapeutic Implications of the Warburg Effect
08:00—11:15
Antibodies for Treatment of Cancer
*
Louis M. Weiner,
Georgetown University Medical Center, USA
Session Chair
Session Chair
Mark X. Sliwkowski,
Genentech, Inc., USA
HER2 Targeted Therapies
HER2 Targeted Therapies
Andrew M. Scott,
Ludwig Institute for Cancer Research, Australia
Targeting a Novel EGFR Epitope on Cancer Cells
Targeting a Novel EGFR Epitope on Cancer Cells
Kerry A. Chester,
University College London Cancer Institute, UK
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) of Cancer
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) of Cancer
Philip E. Thorpe,
University of Texas Southwestern Medical Center, USA
Targeting Exposed Phosphatidylserine on Cancer Blood Vessels: Preclinical and Clinical Studies
Targeting Exposed Phosphatidylserine on Cancer Blood Vessels: Preclinical and Clinical Studies
Kelly J. Davis,
Massachusetts Institute of Technology, USA
Short Talk: Antibody with Picomolar Affinity to DOTA Chelates of Multiple Radionuclides for Pretargeted Radioimmunotherapy
Short Talk: Antibody with Picomolar Affinity to DOTA Chelates of Multiple Radionuclides for Pretargeted Radioimmunotherapy
Mitsuo Satoh,
Research Division, Kyowa Hakko Kirin Company Ltd., Japan
Short Talk: Non-Fucosylated Rituximab Potentiates Human Neutrophil Phagocytosis through its High Binding for FcgammaRIIIb and MHC Class II Expression on the Phagocytotic Neutrophils
Short Talk: Non-Fucosylated Rituximab Potentiates Human Neutrophil Phagocytosis through its High Binding for FcgammaRIIIb and MHC Class II Expression on the Phagocytotic Neutrophils
08:00—11:15
Novel Target Discovery
Alan Ashworth,
University of California, San Francisco, USA
Synthetic Lethal Approaches to the Development of New Therapies Targeting DNA Repair Deficiencies in Cancer
Synthetic Lethal Approaches to the Development of New Therapies Targeting DNA Repair Deficiencies in Cancer
William G. Kaelin, Jr.,
Dana-Farber Cancer Institute, USA
Therapeutic Targets Emerging from Studies of the VHL Tumor Suppressor Protein and 2-Oxoglutarate Dependent Dioxygenases
Therapeutic Targets Emerging from Studies of the VHL Tumor Suppressor Protein and 2-Oxoglutarate Dependent Dioxygenases
Peter A. Jones,
Van Andel Research Institute, USA
Epigenetic Therapy
Epigenetic Therapy
Lynda Chin,
University of Texas MD Anderson Cancer Center, USA
Mining and Translating the Cancer Genome
Mining and Translating the Cancer Genome
Igor Landais,
Oregon Health Sciences University, USA
Short Talk: Identification of Potent Inhibitors of the Fanconi Anemia Pathway Using a Novel Cell-Free Assay
Short Talk: Identification of Potent Inhibitors of the Fanconi Anemia Pathway Using a Novel Cell-Free Assay
Johannes Zuber,
Research Institute of Molecular Pathology, Austria
Short Talk: In-vivo Evaluation of Putative Drug Targets in Chemotherapy-Resistant MLL/AF9-Induced Acute Myeloid Leukemia Using Tet-Regulatable RNAi
Short Talk: In-vivo Evaluation of Putative Drug Targets in Chemotherapy-Resistant MLL/AF9-Induced Acute Myeloid Leukemia Using Tet-Regulatable RNAi
14:30—16:30
Workshop 3: Therapeutic Antibodies in the Neurosciences
Anthony Williamson,
Calmune Corporation, USA
Antibodies for Prion Based Diseases
Antibodies for Prion Based Diseases
Angela R. Jones,
University of Wisconsin - Madison, USA
Short Talk: Identification of Blood-Brain Barrier Targeting and Transporting Antibodies
Short Talk: Identification of Blood-Brain Barrier Targeting and Transporting Antibodies
17:00—19:00
Identifying and Predicting Antibody Efficacy and Toxicity
*
Andrew M. Scott,
Ludwig Institute for Cancer Research, Australia
Session Chair
Session Chair
Peter D. Senter,
Seattle Genetics Inc., USA
Antibody Drug Conjugates for Cancer Therapy
Antibody Drug Conjugates for Cancer Therapy
Birgit Schoeberl,
Novartis Institutes for BioMedical Research, USA
An Attempt to Translate in vitro Responses into the Clinic Using Computationally Predicted Preclinical Data from ErbB Targeted Therapies
An Attempt to Translate in vitro Responses into the Clinic Using Computationally Predicted Preclinical Data from ErbB Targeted Therapies
Richard H.J. Begent,
University College London, UK
Guidelines for Information about Antibody Therapy Experiments; Lessons from the Tegenero Experience
Guidelines for Information about Antibody Therapy Experiments; Lessons from the Tegenero Experience
Max Warncke,
Novartis, Switzerland
Short Talk: Effector Functions of Human IgG Subclasses for Non-Human Primate FcgR
Short Talk: Effector Functions of Human IgG Subclasses for Non-Human Primate FcgR
17:00—19:15
Target Validation
*
William G. Kaelin, Jr.,
Dana-Farber Cancer Institute, USA
Session Chair
Session Chair
Dean Walton Felsher,
Stanford University, USA
Validating Cancer Targets using Conditional Transgenic Mouse Models
Validating Cancer Targets using Conditional Transgenic Mouse Models
Dean Walton Felsher,
Stanford University, USA
Validating Cancer Targets using Conditional Transgenic Mouse Models
Validating Cancer Targets using Conditional Transgenic Mouse Models
Scott W. Lowe,
Memorial Sloan Kettering Cancer Center, USA
Dissecting Tumor Suppressor Gene Networks in vivo
Dissecting Tumor Suppressor Gene Networks in vivo
Peter J. Houghton,
St. Jude Children's Research Hospital, USA
Tumor Xenografts for Target Validation
Tumor Xenografts for Target Validation
Poulikos I. Poulikakos,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: ATP-Competitive Inhibitors of RAF Kinase Inhibit ERK Signaling in Cells Harboring Mutant BRAF, but Activate ERK Signaling in Cells with Wild Type BRAF
Short Talk: ATP-Competitive Inhibitors of RAF Kinase Inhibit ERK Signaling in Cells Harboring Mutant BRAF, but Activate ERK Signaling in Cells with Wild Type BRAF
Amy R. Rappaport,
Cold Spring Harbor Laboratory, USA
Short Talk: MLL/AF9 is Required for the Maintenance of Aggressive Acute Myeloid Leukemia in Mice
Short Talk: MLL/AF9 is Required for the Maintenance of Aggressive Acute Myeloid Leukemia in Mice
08:00—11:15
Antibodies in the Treatment of Autoimmunity, Allergy and Infectious Diseases
*
James D. Marks,
University of California, San Francisco, USA
Session Chair
Session Chair
Ian A. Wilson,
The Scripps Research Institute, USA
Structural Aspects of Antibody Recognition of Influenza
Structural Aspects of Antibody Recognition of Influenza
Dennis R. Burton,
The Scripps Research Institute, USA
Antibodies for HIV Therapy and Vaccine Development
Antibodies for HIV Therapy and Vaccine Development
Tariq Ghayur,
AbbVie, Inc., USA
Dual Variable Domain Immunoglobulins (DVD-Ig TM): A Novel Class of Dual-Specific Biologics
Dual Variable Domain Immunoglobulins (DVD-Ig TM): A Novel Class of Dual-Specific Biologics
08:00—11:00
Translating Targeted Therapy to the Clinic
Alan Colowick,
Gloucester Pharmaceuticals, USA
Clinical Activity of Romidepsin, a pan-HDACi, in the Clinic
Clinical Activity of Romidepsin, a pan-HDACi, in the Clinic
Barbara L. Weber,
Tango Therapeutics, USA
Using Cancer Genomics to Inform Targeted Drug Development
Using Cancer Genomics to Inform Targeted Drug Development
Tak W. Mak,
Campbell Family Institute for Breast Cancer, Canada
Cancer Metabolism: Back to the Future
Cancer Metabolism: Back to the Future
Alice Fan,
Stanford University, USA
Talk Title to be Determined
Talk Title to be Determined
Phillip G. Febbo,
Illumina, Inc., USA
Short Talk: MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through 4EBP1-Mediated Inhibition of Autophagy
Short Talk: MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through 4EBP1-Mediated Inhibition of Autophagy
17:00—19:00
Imaging in Cancer Drug Discovery (Joint)
*
E. Sally Ward,
University of Southampton, UK
Session Chair
Session Chair
*
Roger Y. Tsien,
HHMI/University of California, San Diego, USA
Optical and MR Imaging of Tumors in vivo with Activatable Cell Penetrating Peptides
Optical and MR Imaging of Tumors in vivo with Activatable Cell Penetrating Peptides
Karl Dane Wittrup,
Massachusetts Institute of Technology, USA
Pretargeted Radioimmunotherapy: Predictive Modeling and Experimental Validation
Pretargeted Radioimmunotherapy: Predictive Modeling and Experimental Validation
Anna M. Wu,
University of California, Los Angeles, USA
Engineered Antibodies for Probing Cell Surface Markers in vivo
Engineered Antibodies for Probing Cell Surface Markers in vivo
Sripad Ram,
University of Texas Southwestern Medical Center, USA
Short Talk: 3D Single Molecule Tracking of Antibodies in Live Cells Using Multifocal Plane Microscopy
Short Talk: 3D Single Molecule Tracking of Antibodies in Live Cells Using Multifocal Plane Microscopy
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
|
|
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
